Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients
A 2 arm (1 Active, 1 Active Control) study is to compare the safety and efficacy of
different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in
renal transplant recipients treated with tacrolimus, MMF and a rapid steroid withdrawal.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 Months
A BCAR is a suspected new rejection w/in 6 mos. of skin closure, confirmed by Banff Grade ≥1A assigned by a pathologist. The Banff 97 classification system is used for interpreting histology of allograft biopsies, including Mild (1A/1B), Moderate (2A/2B) & Severe (3). Kaplan Meier analysis was used to estimate % of pts. w/event. Patients w/no event at time of scheduled visit or whose 1st event was after premature discontinuation of study drug/tacrolimus were censored on the scheduled day of a) assessment, b) of premature treatment discontinuation or c) last evaluation, whichever came 1st.
6 months
No
Central Contact
Study Director
Astellas Pharma Global Development
United States: Institutional Review Board
20-04-003
NCT00113269
May 2005
March 2009
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Austin, Texas 78705 | |
Hackensack, New Jersey 07601 | |
Denver, Colorado | |
Charlotte, North Carolina | |
Eugene, Oregon | |
Milwaukee, Wisconsin | |
Charleston, South Carolina | |
Washington, District of Columbia | |
Salt Lake City, Utah 84112 |